BCLI: BrainStorm Cell Therapeutics Inc. PEG Multiple
Brainstorm Cell (BCLI) focuses on the NurOwn platform, where Phase III ALS therapy trials and engagement with the FDA have become key growth drivers. The PEG ratio, based on the work of leading neurobiologists, shows that the parameter value reaches 0.00. The prospects of the NurOwn product as a breakthrough treatment determine the company's current potential within the neuromedicine sector.
Brainstorm Cell (BCLI) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Brainstorm Cell|BCLI - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio brainstorm-cell.com|BCLI - Company Debts|Debts to Book Value Brainstorm Cell|BCLI - Company Long-Term Debt|Company Short-Term Loans and Borrowings BrainStorm Cell Therapeutics|Quick Liquidity Indicator brainstorm-cell.com
- net income and valuation ratios data:
BCLI - Net Income|Expected Net Income Brainstorm Cell|BCLI - P/E Multiple|Projected Price to Earnings BrainStorm Cell Therapeutics Inc.|BCLI - PEG Multiple|Company Value to EBITDA Brainstorm Cell|BCLI - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months brainstorm-cell.com|BCLI - Earnings growth in current year|Net earnings per share growth forecast for next year Brainstorm Cell
Fundamental company analysis:BCLI - Brainstorm Cell Therapeutics Inc.
The diversified cell therapy pipeline of Brainstorm Cell (BCLI) for treating neurodegenerative diseases mitigates regulatory risks, making the analysis of the PEG ratio chart critically important. This indicator compares the current P/E to earnings growth rates, allowing investors to distinguish fundamental undervaluation from a "value trap"; a value below one signals potential for share price growth relative to the company's income dynamics.
Competitors of Brainstorm Cell
BIIB (Biogen Inc) - Growth-Adjusted Payback Ratio|PEG Multiple NBIX (Neurocrine Biosciences Inc)|PEG Multiple Regencell Corp RGC|Axsome Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income acadia-pharm.com ACAD|Xenon (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus Pharma|Catalyst Corp (CPRX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics)|Company Value to Earnings Growth Ratio HRMY|Price/Earnings to Growth Ratio Biohaven BHVN|Amylyx Pharmaceuticals Inc (AMLX) - Price to Earnings Adjusted for Growth Rate|TRVI - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio PRAX (Praxis Corp)|Anavex Life Sciences (AVXL) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple ceribell.com|Price/Earnings to Growth Multiple PRTA|ALEC: Growth-Adjusted Payback Ratio|PEG Multiple ANNX|Price/Earnings to Growth Multiple omeros.com OMER|PEG Multiple NGNE (Neurogene Inc.)|acimmune.com (ACIU) - Price to Earnings Adjusted for Growth Rate|VYGR - Price/Earnings to Growth Ratio|NMRA: Price/Earnings to Growth Ratio|Scilex Holding Co. (SCLX) - Price/Earnings to Growth Ratio|TVGN (Tevogen Bio Inc.) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Inc) - PEG Multiple|Price/Earnings to Growth Ratio CGTX|PEG Multiple IKT|Price/Earnings to Growth Multiple Cassava Sciences Inc SAVA|Price/Earnings to Growth Ratio Assertio ASRT|Coya Therapeutics Inc - Price/Earnings to Growth Ratio|VistaGen Therapeutics Inc - PEG Multiple|Growth-Adjusted Market Cap to Net Income Ovid Therapeutics Inc. OVID|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio CRVO|ATHE (Alterity Therapeutics Ltd.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Clene Nanomedicine CLNN|Price/Earnings to Growth Multiple PEPG (PepGen Inc.)|PEG Multiple jupiterneurosciences.com (JUNS)|Price/Earnings to Growth Ratio Relmada Therapeutics, Inc. RLMD|Growth-Adjusted Payback Ratio ANVS|GRCE - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Firefly Neuro|KLTO: PEG Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Ratio Reviva Pharmaceuticals Holdings, Inc.|MTVA: Growth-Adjusted Payback Ratio|PEG Multiple NRXS|PEG Multiple heliusmedical.com (HSDT)|PEG Multiple PASG (Passage Bio)|Growth-Adjusted Market Cap to Net Income Neuphoria Therapeutics, Inc. (NEUP)|NERV - Price/Earnings to Growth Ratio|ATHA (Athira Pharma Inc) - Growth-Adjusted P/E Ratio|Addex Therapeutics, Ltd. (ADXN) - Price/Earnings to Growth Ratio|ALZN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple CYCN|PTIX (Protagenic) - Company Value to Earnings Growth Ratio|Price/Earnings to Growth Ratio Pasithea Therapeutics (KTTA)|CRGT - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Avenue Therapeutics, Inc ATXI|Growth-Adjusted Payback Ratio CARA|CHRO - Price/Earnings to Growth Ratio|Eliem Therapeutics (ELYM) - Price/Earnings to Growth Multiple|ITCI (intracellulartherapies.com) - Price/Earnings to Growth Multiple|Longboard Pharmaceuticals Inc - Growth-Adjusted Payback Ratio|MRNS (Marinus) - PEG Multiple|Price/Earnings to Growth Multiple NKGen Biotech Corp (NKGN)|PEG Multiple NRBO|SAGE - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Synaptogenix SNPX|Trevena Inc. - Price/Earnings to Growth Ratio|VIGL - Price/Earnings to Growth Ratio|WENA: Price/Earnings to Growth Ratio|CERE: PEG Multiple
